Gilboa Therapeutics

Gilboa Therapeutics is a preclinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies that harness the power of the patient’s immune system. Our mission is to enable more patients to respond to therapies and improve outcomes. Our proprietary SolidT technology, developed in Dr. Yaron Carmi’s lab, provides engineered T cell therapy intended for combination with tumor-specific antibodies to target a variety of solid tumors with unprecedented safety and efficiency. Unlike conventional CAR-T therapies, which have limited efficacy in solid tumors, our breakthrough approach targets tumor cells while sparing healthy tissue, aiming to significantly enhance patient response rates and save lives.